

# WHO guideline

---

on the dairy protein content  
in ready-to-use therapeutic foods  
for treatment of uncomplicated  
severe acute malnutrition



World Health  
Organization



# WHO guideline

---

on the dairy protein content  
in ready-to-use therapeutic foods  
for treatment of uncomplicated  
severe acute malnutrition



World Health  
Organization

WHO guideline on the dairy protein content in ready-to-use therapeutic foods for treatment of uncomplicated severe acute malnutrition

ISBN 978-92-4-002227-0 (electronic version)

ISBN 978-92-4-002228-7 (print version)

**© World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CCBY-NC-SA3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO guideline on the dairy protein content in ready-to-use therapeutic foods for treatment of uncomplicated severe acute malnutrition. Geneva: World Health Organization; 2021. Licence: [CCBY-NC-SA3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Cover photo by Jean-Philippe Delberghe on Unsplash

Design by minimum graphics

# Contents

<b>Publication history</b>	<b>vi</b>
<b>Acknowledgements</b>	<b>vii</b>
Financial support	vii
<b>Abbreviations</b>	<b>viii</b>
<b>Executive summary</b>	<b>ix</b>
Purpose of the guideline	ix
Guideline development methodology	ix
Available evidence	x
Recommendations and rationale	xi
Research gaps	xi
<b>Scope and purpose</b>	<b>1</b>
<b>Background</b>	<b>2</b>
The global burden of severe acute malnutrition	2
History of RUTF	2
Composition of RUTF	2
Protein quality and quantity in RUTF	3
Alternative RUTF formulations	3
Why is it important for WHO to develop this guideline?	3
Aim of the guideline	4
Target audience	4
Scope	4
Population of interest	5
Priority questions	5
Outcomes of interest	5
Assessment of certainty of evidence	6
<b>Guideline development process</b>	<b>7</b>
WHO steering committee	7
Guideline development group	7
Systematic review teams	8
Management of conflicts of interests	8
Identification of priority questions and outcomes	9
Evidence identification and retrieval	9

Quality assessment and grading of evidence	9
Formulating the recommendations	10
Decision-making during the guideline development group meeting	10
<b>Evidence summary</b>	<b>11</b>
Summary of the evidence	11
<b>Summary of the considerations</b>	<b>25</b>
Remarks	26
Recommendation	27
<b>Research gaps</b>	<b>28</b>
<b>External peer review</b>	<b>30</b>
<b>Implementation of the guideline</b>	<b>31</b>
Implementation considerations	31
Regulatory considerations	31
Monitoring and evaluation of guideline implementation	31
<b>Dissemination and plans for updating</b>	<b>32</b>
Dissemination	32
Plans for updating the guideline	32
<b>References</b>	<b>33</b>
<b>Annexes</b>	
Annex 1. Nutritional composition of RUTF	37
Annex 2. Key questions in a population, intervention, comparator and outcomes (PICO) format	38
Annex 3. Characteristics of the trials included in the systematic review for effectiveness outcomes	39
Annex 4. Evidence-to-decision tables	40
Annex 5. Guideline development group members	49
Annex 6. Observers	50
Annex 7. Systematic review team members	51
Annex 8. Peer reviewers	52
Annex 9. WHO steering committee members	53

**List of tables**

Table 1.	GRADE evidence profile	19
Table 2.	Standard RUTF formulation cost estimates (2013)	23
Table 3.	UNICEF tender results for alternative versions of RUTF (2019)	23

**List of figures**

Fig. 1.	Risk of bias of individual trials	12
Fig. 2.	Meta-analysis of the rate of weight gain in grams per kilogram of body weight per day	13
Fig. 3.	Cumulative meta-analysis of the rate of weight gain in grams per kilogram of body weight per day	14
Fig. 4.	Subgroup meta-analysis of the rate of weight gain in grams per kilogram of body weight per day	14
Fig. 5.	Meta-analysis of recovery	15
Fig. 6.	Cumulative meta-analysis of recovery	16
Fig. 7.	Meta-analysis of time to recovery in days	16
Fig. 8.	Meta-analysis of mortality	17
Fig. 9.	Meta-analysis of default rates	17
Fig. 10.	Meta-analysis of non-response	18
Fig. 11.	RUTF macro cost breakdown	22
Fig. 12.	Strategies to reduce the cost of treatment for severe acute malnutrition	24

# Publication history

This is a new World Health Organization (WHO) guideline that updates the specific recommendation in the technical annex of the 2007 Joint Statement by WHO, the World Food Programme (WFP), the United Nations System Standing Committee on Nutrition (UNSSCN) and the United Nations Children's Fund (UNICEF) on community-based management of severe acute malnutrition, which states that at least 50% of protein in ready-to-use therapeutic foods (RUTF) should come from dairy products.

The rigorous procedures described in the *WHO handbook for guideline development, 2nd edition* were followed in producing this guideline. This document presents the direct and indirect evidence that served to inform the recommendation herein.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23983](https://www.yunbaogao.cn/report/index/report?reportId=5_23983)

